Glenmark Life Sciences Limited (IN:ALIVUS)
:ALIVUS
Want to see IN:ALIVUS full AI Analyst Report?
ALIVUS Stock Chart & Stats
₹920.80
-₹16.95(-1.62%)
At close: 4:00 PM EST
₹920.80
-₹16.95(-1.62%)
Day’s Range― - ―
52-Week Range₹830.00 - ₹1,149.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)7.13K
Market Cap
₹127.15B
Enterprise Value₹128.07B
Total Cash (Recent Filing)₹6.53B
Total Debt (Recent Filing)₹1.13B
Price to Earnings (P/E)18.4
Beta0.82
Next Earnings
Jul 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.56%
Share Statistics
EPS (TTM)22.17
Shares Outstanding122,736,350
10 Day Avg. Volume3,315
30 Day Avg. Volume7,125
Financial Highlights & Ratios
PEG Ratio1.32
Price to Book (P/B)3.59
Price to Sales (P/S)4.69
P/FCF Ratio46.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)49.8
Revenue Forecast (FY)₹27.70B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetExtremely low leverage (debt-to-equity ~0.02) and a large equity base provide significant financial flexibility and resilience. With solid ROE (~17%) and minimal interest burden, the company can fund capacity, regulatory spend or withstand downturns without stressing solvency.
Sharp Revenue AccelerationRevenue surged +114.4% YoY in FY2026 after steadier prior growth, signaling meaningful demand, successful commercialization or scaling. Durable top-line expansion supports fixed-cost absorption, scale economics and a stronger growth runway if regulatory access and mix remain favorable.
High Operating ProfitabilitySustained high margins (gross ~44.6%, EBIT ~28–30%, net ~22.1%) reflect pricing power and efficient API manufacturing. Such operating profitability generates internal funding for reinvestment and strengthens competitive position in manufacturing and process development over the medium term.
Bears Say
Weak Cash ConversionFree cash flow at only ~0.46x of net income indicates working capital or capex materially absorb earnings. Structural lower cash conversion limits the company's ability to self-finance growth, dividends or unexpected spending and increases reliance on capital allocation discipline.
Margin Volatility RiskReported margin volatility versus earlier peaks suggests susceptibility to product-mix shifts, pricing pressure or cost swings. For an API supplier, such variability reduces earnings predictability and means margins could erode if high-margin product volumes decline or if competitive pricing intensifies.
Operational And Customer Concentration RisksRevenue depends on capacity utilization, regulatory approvals and customer mix; concentrated customers or regulatory setbacks can cause meaningful revenue swings. These structural dependencies amplify operational risk and make medium-term revenue visibility contingent on execution and compliance.
Glenmark Life Sciences Limited News
ALIVUS FAQ
What was Glenmark Life Sciences Limited’s price range in the past 12 months?
Glenmark Life Sciences Limited lowest stock price was ₹830.00 and its highest was ₹1149.00 in the past 12 months.
What is Glenmark Life Sciences Limited’s market cap?
Glenmark Life Sciences Limited’s market cap is ₹127.15B.
When is Glenmark Life Sciences Limited’s upcoming earnings report date?
Glenmark Life Sciences Limited’s upcoming earnings report date is Jul 31, 2026 which is in 66 days.
How were Glenmark Life Sciences Limited’s earnings last quarter?
Glenmark Life Sciences Limited released its earnings results on May 14, 2026. The company reported ₹14.1 earnings per share for the quarter, beating the consensus estimate of ₹11.7 by ₹2.4.
Is Glenmark Life Sciences Limited overvalued?
According to Wall Street analysts Glenmark Life Sciences Limited’s price is currently Overvalued.
Does Glenmark Life Sciences Limited pay dividends?
Glenmark Life Sciences Limited pays a Semiannually dividend of ₹22.5 which represents an annual dividend yield of 0.56%. See more information on Glenmark Life Sciences Limited dividends here
What is Glenmark Life Sciences Limited’s EPS estimate?
Glenmark Life Sciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Glenmark Life Sciences Limited have?
Glenmark Life Sciences Limited has 122,736,350 shares outstanding.
What happened to Glenmark Life Sciences Limited’s price movement after its last earnings report?
Glenmark Life Sciences Limited reported an EPS of ₹14.1 in its last earnings report, beating expectations of ₹11.7. Following the earnings report the stock price went down -1.747%.
Which hedge fund is a major shareholder of Glenmark Life Sciences Limited?
Currently, no hedge funds are holding shares in IN:ALIVUS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Glenmark Life Sciences Limited
Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally. It offers various APIs, such as olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib for various therapeutic areas, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, immunosuppressant, respiratory and ophthalmologic agents, urology, and anti-infectives. The company also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. It exports its products. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was founded in 2001 and is based in Mumbai, India. Alivus Life Sciences Limited is a subsidiary of Nirma Limited.
Technical Analysis
Caplin Point Laboratories Limited
―
Granules India Limited
―
Marksans Pharma Limited
―
Sanofi India Limited
―
Shilpa Medicare Limited
―